Inactive Instrument

Syncom Healthcare Limited

SYNCOM

INE602K01014

Syncom Healthcare Limited Appoints Farida Bhatia as Company Secretary Cum Compliance Officer of the Company

April 01, 2019 at 07:35 am EDT

Syncom Healthcare Limited announced that Mrs. Farida Bhatia has been appointed as Company Secretary cum Compliance Officer of the Company with effect from 01 April, 2019.

Latest news about Syncom Healthcare Limited

Syncom Healthcare Limited Announces Unaudited Standalone Earnings Results for the First Quarter Ended June 30, 2021	21-08-14	CI
Syncom Healthcare Limited Announces Audited Standalone Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2021	21-06-30	CI
Syncom Healthcare Limited Announces Resignation of Farida Bhatia as Company Secretary Cum Compliance Officer	21-03-23	CI
Syncom Healthcare Limited Reports Unaudited Standalone Earnings Results for the Third Quarter and Nine Months Ended December 31, 2020	21-02-14	CI
Syncom Healthcare Limited Reports Unaudited Standalone Earnings Results for the Second Quarter and Six Months Ended September 30, 2020	20-11-13	CI
Syncom Healthcare Limited Reports Unaudited Standalone Earnings Results for the First Quarter Ended June 30, 2020	20-09-15	CI
Syncom Healthcare Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2020	20-06-23	CI
Syncom Healthcare Limited Reports Unaudited Standalone Earnings Results for the Third Quarter and Nine Months Ended December 31, 2019	20-02-14	CI
Syncom Healthcare Limited Announces Address Change	19-12-05	CI
Syncom Healthcare Limited Reports Unaudited Standalone Earnings Results for the Second Quarter and Six Months Ended September 30, 2019	19-11-18	CI
Syncom Healthcare Limited Announces Board Changes	19-10-01	CI
Syncom Healthcare Limited Reports Earnings Results for the Full Year Ended March 31, 2019	19-09-06	CI
Syncom Healthcare Limited Reports Unaudited Standalone Earnings Results for the First Quarter Ended June 30, 2019	19-08-14	CI
Syncom Healthcare Limited Announces Audited Standalone Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2019	19-05-30	CI
Syncom Healthcare Limited Appoints Bhishampal Singh Yadav as Additional Director	19-05-30	CI
Syncom Healthcare Limited Announces Sad Demise of Jagdish Soneja, Non-Executive Independent Director	19-04-25	CI
Syncom Healthcare Limited Appoints Farida Bhatia as Company Secretary Cum Compliance Officer of the Company	19-04-01	CI
Syncom Healthcare Limited Announces Resignation of Charu Srivastava as Company Secretary Cum Compliance Officer	19-04-01	CI
Syncom Healthcare Limited Announces Resignation of Bhishampal Singh Yadav from the Post of Director and Whole Time Director	19-03-04	CI
Syncom Healthcare Limited Announces Unaudited Standalone Earnings Results for Third Quarter and Nine Months Ended December 31, 2018	19-02-14	CI
Syncom Healthcare Limited Appoints Manoj Negi as Executive Additional Director	19-01-31	CI
Syncom Healthcare Limited Reports Unaudited Standalone Earnings Results for the Second Quarter and Six Months Ended September 30, 2018	18-11-14	CI
Syncom Healthcare Limited Reports Unaudited Standalone Earnings Results for the First Quarter Ended June 30, 2018	18-08-16	CI
Syncom Healthcare Limited Announces Bhishampal Singh Yadav Withdrawn his Resignation	18-06-19	CI
Syncom Healthcare Limited Announces Audited Standalone Earnings Results for the Fourth Quarter and Full Year and Consolidated Earnings Results for the Full Year Ended March 31, 2018	18-05-29	CI

Chart Syncom Healthcare Limited

Duration

Period

More charts

Syncom Healthcare Limited is engaged in manufacturing of pharmaceuticals. The Company is an integrated international pharmaceutical company with businesses encompassing the value chain in the marketing, production (including job work) and distribution of pharmaceutical products. The Company operates through pharmaceuticals formulations segment. The Company in the domestic market, has approximately two main focus areas of operations: contract/toll manufacturing and over the counter (OTC). Through its OTC operations, the Company functions in three segments namely, generic, ethical, and the pharma OTC. The Company undertakes contract manufacturing for various pharmaceutical formulations, neutraceutical products, food supplements and cosmetics, which include tablets, capsules, syrups/liquid orals, eye-ear drops, creams and ointments, oral dry powders (Non-beta lactam), protein powders, external preparations (Oils and Liniments) and herbal preparations.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+48.53%	780B
NOVO NORDISK A/S	+40.67%	627B
JOHNSON & JOHNSON	-6.37%	353B
MERCK & CO., INC.	+20.93%	334B
ABBVIE INC.	+8.21%	296B
ASTRAZENECA PLC	+16.75%	244B
ROCHE HOLDING AG	-1.19%	217B
NOVARTIS AG	+10.85%	214B
AMGEN INC.	+4.40%	161B

Other Pharmaceuticals